Pfizer finally begins Phase III for GlycoMimetics sickle cell drug
This article was originally published in Scrip
Executive Summary
GlycoMimetics will receive the final $20m of a $35m milestone payment from Pfizer now that the big pharma company has initiated a long-delayed Phase III clinical trial for rivipansel (GMI-1070) in the treatment of patients hospitalized for painful vaso-occlusive crises associated with sickle cell disease.
You may also be interested in...
Sickle Cell Data Show Value Of Novartis’s Recently Acquired SEG101
Phase II SUSTAIN data presented at ASH show a statistically significant reduction in sickle cell pain crises for SEG101 (crizanlizumab), a potential blockbuster for Novartis, which recently said it will pay up to $665m for the antibody’s developer.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.